Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

Publication date: Available online 1 October 2020Source: The Lancet HaematologyAuthor(s): Bruce D Cheson, Nancy L Bartlett, Betsy LaPlant, Hun J Lee, Ranjana J Advani, Beth Christian, Catherine S Diefenbach, Tatyana A Feldman, Stephen M Ansell
Source: The Lancet Haematology - Category: Hematology Source Type: research